FDA gave approval to Oligomannate 甘露寡糖二酸 (otherwise referred to as GV-971), developed by Chinese company Shanghai Green Valley Pharmaceuticals 上海绿谷制药 to progress to international multi-center clinical trials involving 2,000 mild and moderate Alzheimer’s cases.
9-25-20 Phase II trial – GV-971 was safe and well tolerated. GV-971 900 mg was chosen for phase III clinical study.
